News

Focal Upright Furniture introduces portable, lightweight seat

BY Jason Owen

NEW YORK — Focal Upright Furniture announced on Tuesday the introduction of its newest ergonomic product innovation: the Mogo.

The Mogo is a portable, recreational upright seat designed ergonomically for consumers on-the-go. At only 2 lbs., the Mogo seat is a convenient new product that helps achieve good posture wherever it is used. The Mogo seat allows for interchangeable bases, giving consumers added flexibility to use it on hard or soft surfaces.

Focal Upright Furniture is best known for its Locus Workstation innovation, a desk the company hopes will fundamentally change the way people work. The Locus Workstation is used in the offices of Google and Wikimedia, the company noted.

Focal Upright Furniture designer, founder and CEO Martin Keen will formally unveil the new Mogo seat to the media at the company’s SOHO showroom in New York City from August 5 to 7.

The Mogo seat has a suggested retail price of about $100, representatives for the company stated.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Minn. tobacco tax increase boosts smoking-cessation program’s enrollment

BY Alaric DeArment

EAGAN, Minn. — An increase in tobacco taxes in Minnesota has nearly tripled enrollment in a health plan’s smoking-cessation program.

Blue Cross and Blue Shield of Minnesota said enrollment in its Stop Smoking Support program had nearly tripled since a $1.60 increase in the state tobacco tax took effect at the beginning of this month. The program enrolled 186 people in the first two weeks of July, compared with 69 people in the first two weeks of July 2012.

"Blue Cross advocated for this legislation because price increases have proven to be the most effective way to encourage people to quit using tobacco and ultimately live longer, healthier lives," Blue Cross Center for Prevention director Janelle Waldock said. "While our members represent only a segment of Minnesota residents, this early surge in demand for our cessation services is a positive indicator that the price increase is having its desired effect."

The most recent Minnesota Adult Tobacco Survey had found that smoking among adults in the state dropped from 19.1% to 16.1% between 2003 and 2010.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Health Canada approves GSK’s Tafinlar, Mekinist

BY Alaric DeArment

MISSISSAUGA, Ontario — Canadian regulators have approved two drugs made by GlaxoSmithKline for treating skin cancer, GSK said Wednesday.

The drug maker announced Health Canada’s approval of Tafinlar (dabrafenib mesylate) and Mekinist (trametinib) in patients with melanoma that can’t be removed by surgery or has spread to other parts of the body.

"Health Canada’s approvals of Tafinlar and Mekinist represent an important step in GSK’s ongoing effort to bring new treatment options to cancer patients as quickly and efficiently as possible," GSK Canada VP research and development operations, and business development Rav Kumar said. "With Tafinlar and Mekinist, we hope to make a meaningful difference in the lives of patients living with metastatic melanoma, a devastating disease with very low survival rates and limited treatment options."


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?